IL-33/ST2 pathway in the immune response towards melanoma

Project objectives

 The primary objective of the study is to evaluate whether interleukin (IL)-33 plays a positive or negative role in the anti-tumor immune response elicited during melanoma development and metastatic progression. By studying the events regulated by IL-33 or its soluble receptor ST2, both locally and systemically, and its direct action on melanoma cells, we expect to gain new insights into the therapeutic potential of the IL-33/ST2 axis in the anti-tumor response to melanoma. 

Start and end date

01/01/2013 - 01/01/2015

Project Manager

Dr Silvia Angeletti

Coordinating institution of the project

Istituto Superiore di Sanita

Funding source(s).